Baxter’s Split Into Two Companies Bears Similarity To Abbott’s Biopharma Spinout
This article was originally published in The Pink Sheet Daily
Executive Summary
The Illinois-based company will spin out its biopharma business by mid-2015, creating two public companies that will cater to vastly different markets. Yet, both companies are expected to boast strong balance sheets and be in position to make acquisitions.